Metrics cut 1
- Oncology growth guidance cut to 10-12% (from ~25%+ earlier)
Friday, August 7, 2026, 11:00 AM IST
Event Participants
Executives
5 Anurag Kalra, Ashutosh Raghuvanshi, Akshay Tiwari, Vijender Singh, Vivek Kumar Goyal
Analysts
10 Abdulkader Puranwala, Aman Goyal, Damayanti Kerai, Deepthi Rajulapati, Gopal Bhatt, Karan Vora, Neha Manpuria, Nilay Parekh, Saion Mukherjee, Tausif Shaikh
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹2,545 crores | +17.5% YoY; steady start across hospitals and diagnostics |
| Hospital Revenue | ₹2,187 crores | +19% YoY; includes recent Punjab, Bengaluru and Delhi NCR acquisitions |
| Agilus Gross Revenue | ₹407 crores | +10.2% YoY; growth driven by volume and better test mix |
| Consolidated EBITDA (pre-ESOP) | ₹568 crores | +15.8% YoY; margin 22.3% vs 22.6% in Q1 FY26 |
| Hospital EBITDA | ₹471 crores | Margin 21.5% vs 22.1% YoY; like-for-like (ex-acquisitions) margin flat at 22% |
| Agilus EBITDA | ₹97 crores | Margin improved to 23.9% from 23.0% YoY on operating leverage and richer test mix |
| Consolidated PAT (pre-exceptional) | ₹263 crores | +4% YoY |
| Hospital Occupancy | 69% | Flat YoY; occupied beds up 17% to 3,418 beds |
| ARPOB | ₹2.71 crores/annum | +2.6% YoY |
| Net Debt | ₹2,233 crores | vs ₹1,869 crore in Jun'25; increase due to last year's acquisitions |
| Net Debt-to-EBITDA | 1.01x | vs 0.92x in Jun'25 |
| Hospital Facilities with EBITDA >20% | 14 facilities | vs 13 in FY26; contributes >70% of hospital revenue |
| Beds Added (Q1) | ~100 beds | Brownfield expansion across Noida, Amritsar, Jalandhar |
| International Business Revenue | ₹174 crores | +13.3% YoY; ~8% of total revenue |
| Agilus Customer Touchpoints | 4,493 | Gross additions of 200+ during the quarter |
| Agilus B2C:B2B Mix | 53:47 | Improved from 51:49 in Q1 FY26 |
| Agilus Preventive Portfolio Share | 14% | up from 12% YoY |
| Agilus Specialized Portfolio Share | 35% | up from 34% YoY |
| Agilus Tests Processed | ~10.5 million | During the quarter |
Geographic & Segment Commentary
Hospitals - Key Specialties: Renal Sciences (+28% YoY), Neurosciences (+27%) and Orthopedics (+23%) led growth. Oncology growth decelerated to ~5% from ~24% earlier, impacted by the 30% MRP discount on chemotherapy drugs under CGHS/ECHS; management now guides oncology growth at 10-12% with focus shifting to radiation and surgical oncology.
Hospitals - Mature Facilities: 14 facilities with >20% EBITDA margin now contribute over 70% of hospital revenue. Jaipur, Noida, Faridabad and Mulund reported margin expansion; Mulund and Faridabad registered revenue growth in excess of 20% YoY. FMRI maintains ~25% EBITDA margins with 200 new beds nearing operationalization.
Hospitals - Ramping Units: Manesar (187 beds operational, ~60% occupancy) and Greater Noida (monthly revenue growth 8-10%) are expected to reach mid-teens EBITDA by year-end. Radiation oncology equipment at Manesar to be commissioned by November, converting it into a comprehensive oncology center.
Hospitals - International Business: Revenue of ₹174 crores, +13.3% YoY, contributing ~8% of total revenue, consistent with prior year.
Agilus Diagnostics: B2C mix improved to 53:47 (from 51:49), with preventive and specialized portfolio contributions at 14% and 35% respectively. Completed 1,000+ whole exome sequencing tests on NovaSeq X platform at Mumbai Global Reference Laboratory. Management targets B2C mix of 55-58% over the medium term, with double-digit revenue growth and 24-25% EBITDA margins for the rest of the year.
Company-Specific & Strategic Commentary
ESOP Scheme: Broad-based Employee Stock Option Plan rolled out effective April 23, 2026, covering 55-60% doctors and balance senior staff/admin across all zones (not Delhi NCR-specific). Planned over 1.5 years as a retention and performance-alignment tool—not a reactionary response to poaching. Charge ~₹40 crores/quarter initially, declining to ~₹30 crores and then ~₹25 crores in subsequent years.
Bed Expansion: 100 beds added in Q1 via brownfield expansion (Noida, Amritsar, Jalandhar); 400 more beds expected in remaining three quarters, with FMRI contributing 200 beds (occupancy certificate expected imminently). Total 2,000-bed brownfield expansion program underway.
Oncology Infrastructure: Board approved Proton therapy facility at flagship Gurgaon hospital, capex ~₹252 crores including operations. Da Vinci Xi robotic systems installed at Faridabad and Fortis Escorts Okhla; ortho robots at Jalandhar and Faridabad. Manesar, Faridabad, Amritsar and Jaipur progressing toward full comprehensive cancer center capability.
Qatar O&M Entry / New Markets: Signed O&M agreement for 300-bed greenfield multi-specialty hospital in Odisha—no capital commitment; positions Fortis for future participation in the region's growth. Cluster strategy remains intact (Delhi NCR, Bengaluru, Punjab, Mumbai, Kolkata, Hyderabad, Chennai), with M&A targets focused on existing clusters.
Gleneagles O&M: Managing 5 hospitals under 3% of revenue fee structure (~₹6 crores/quarter). Operations improving but not yet fully stabilized to Fortis standards; expected full stabilization in 2-4 quarters.
Inorganic Growth: Evaluating deals in existing clusters; no call options on current O&M contracts except ongoing discussions with IHH regarding Gleneagles assets.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Consolidated EBITDA Margin | 25% by FY28 (post-ESOP) | Management reaffirmng guidance post-ESOP rollout; to be driven by new units (negative 0.4% contribution turning to +1%), doctor productivity, legal cost normalization, provision recovery and Manesar/FMRI ramp-up |
| FY27 Hospital EBITDA Margin | ~150-200 bps expansion (ex-ESOP, original guidance basis) | Maintained; Like-for-like margin flat in Q1; improvement expected from H2 as new units ramp |
| Bed Additions (FY27) | ~500 total beds (100 done, 400 remaining) | FMRI (200 beds) biggest contributor; other brownfield expansions on track |
| Agilus Diagnostics Revenue Growth | 12-13% for remaining FY27 | From current 10.2%; driven by B2C mix shift, preventive/specialized portfolio expansion |
| Agilus EBITDA Margin | 24-25% for remaining FY27 | From 23.9% in Q1; operating leverage and test mix improvement |
| Capex | ~50% of EBITDA for FY27 | Brownfield expansion, robotics, proton therapy, other tech initiatives |
| Manesar & Noida EBITDA Margins | Mid-teens by end of FY27 | Manesar oncology commissioning (by Nov'26) a key catalyst; Noida monthly growth 8-10% on revenue |
Risks & Constraints
| Risk | Context |
|---|---|
| Chemo Pricing Impact (CGHS/ECHS) | 30% MRP discount on chemotherapy drugs has cut oncology revenue growth from ~24% to ~5%; management pivoting to radiation and surgical oncology to offset; oncology growth now expected at 10-12% not 25%+ |
| ESOP Dilution to Margins | ~₹40 crores/quarter charge initially (declining to ₹25 crores); CFO expects offsetting gains from doctor alignment, reduced poaching-related costs and efficiency improvements; margin guidance maintained but with execution risk |
| New Unit Ramp-Up Execution | Manesar (187 beds, 60% occupancy) and Greater Noida yet to reach target profitability; management targets mid-teens by year-end but assumes occupancy picks up and oncology comes on-stream as planned |
| Government/TPA Receivables | Provision for doubtful debts increased materially due to delayed collections from government schemes and TPAs; team working to plug; legal costs from Delhi High Court hearings also burdened Q1 profitability |
| Competitive Pressure on Talent | Attrition elevated in micro-markets (e.g., Noida with new hospital openings); management sees improving supply of clinical talent from expanded medical college seats; ESOP scheme designed to counter poaching risk |
| Diagnostic Market Competition | Agilus growth (10.2%) lags industry (~15%); rebranding and network rationalization impacted volumes; new leadership (Vijender Singh) expected to accelerate growth but recovery timeframe uncertain |
| Odisha O&M Capital Commitment | O&M structure limits downside, but no call option exists to participate in equity upside; could limit strategic optionality if the asset performs well |
Q&A Highlights
ESOP Rationale & Design
- Question: What was the criteria for choosing the doctor pool for ESOPs, and was it a reaction to poaching attempts in Delhi NCR? (Tausif Shaikh, BNP Paribas)
- Answer: ESOPs designed as a broad-based retention and alignment tool—not limited to Delhi NCR but across all zones. Planned over 1.5 years, not reactionary. Alignment ensures doctors participate in cost control and efficiency initiatives. ESOP charge expected ~₹40 crores/quarter initially, declining to ~₹30 crores then ~₹25 crores. (Ashutosh Raghuvanshi, Vivek Goyal)
Margin Guidance & ESOP Impact
- Question: Is the 25% EBITDA margin by FY28 pre- or post-ESOP? (Neha Manpuria, BofA Securities; Damayanti Kerai, HSBC; Karan Vora, Goldman Sachs)
- Answer: Guidance originally given pre-ESOP approval, but management now committing to 25% post-ESOP by FY28. Offsetting levers include new units (currently -0.4% contribution turning to +1%), reduced doctor poaching costs, lower legal costs, provision reversals and ramp-up of Manesar/FMRI. (Vivek Goyal, Ashutosh Raghuvanshi)
Manesar & Greater Noida Ramp-Up
- Question: When will Manesar and Greater Noida reach 20% margins, and what's the bed status? (Neha Manpuria, BofA)
- Answer: Manesar has 187 beds operational at ~60% occupancy with final approvals pending for last two floors; radiation oncology equipment installation complete by November, transforming it into a comprehensive oncology center. Noida growing 8-10% MoM on revenue. Both expected to hit mid-teens EBITDA by year-end. (Ashutosh Raghuvanshi)
Margin Expansion Levers
- Question: What are the specific building blocks to reach 25% EBITDA margin? (Karan Vora, Goldman Sachs)
- Answer: Five levers: (1) new units flipping from -0.4% to +1% contribution, (2) new doctors settling into productivity, (3) normalization of legal costs, (4) recovery of doubtful debt provisions from government/TPAs, (5) occupancy improvement at low-occupancy hospitals like BG Road and Mulund. (Vivek Goyal)
Bed Expansion Timeline
- Question: What is the bed operationalization plan over the next 3-4 quarters? (Karan Vora, Goldman Sachs)
- Answer: 100 beds added in Q1; 400 more expected in remaining three quarters, with FMRI (200 beds, occupancy certificate imminent—possibly this month) as the main contributor. (Vivek Goyal)
Odisha O&M & Cluster Strategy
- Question: How does entering Odisha fit with the cluster strategy? (Damayanti Kerai, HSBC)
- Answer: Odisha is an O&M project with zero capital commitment—a learning opportunity, not a cluster shift. Core focus remains existing clusters (Bengaluru, Delhi NCR, Punjab, Mumbai, Kolkata, Hyderabad, Chennai) with M&A evaluated only in these markets. (Ashutosh Raghuvanshi)
Gleneagles O&M Status & Fees
- Question: What's the improvement trajectory and management fees from Gleneagles hospitals? (Damayanti Kerai, HSBC; Aman Goyal, IIFL)
- Answer: Operations improving but not yet to Fortis standards—expect 2-4 quarters to fully stabilize. Fee is 3% of revenue (~₹6 crores/quarter) per agreement, being received in full. (Ashutosh Raghuvanshi, Vivek Goyal)
Oncology Growth Deceleration
- Question: What's driving the 200 bps decline in oncology revenue share? (Aman Goyal, IIFL; Gopal Bhatt, Baroda BNP Paribas)
- Answer: Chemo drug pricing reforms (30% MRP discount under CGHS/ECHS) have muted oncology growth to ~5% from ~24%. ECHS overall contribution remains flat—procedure/diagnostic prices rose while chemo prices fell. Future oncology growth guided at 10-12% with focus on radiation and surgical oncology. (Ashutosh Raghuvanshi)
Diagnostic Business Growth Lag
- Question: Industry is growing at ~15% but Agilus at 10.2%—what challenges remain? (Aman Goyal, IIFL)
- Answer: Prior brand change and lab network rationalization suppressed growth; volumes are returning and NCR region shows strong improvement under focused efforts. New leadership (Vijender Singh, 10 days in role) brings scale-building experience—targeting industry-parity growth within next few quarters and B2C mix of 55-58%. (Ashutosh Raghuvanshi, Vijender Singh)
Proton Therapy Capex & O&M Options
- Question: What's the capex and timeline for proton therapy? (Deepthi Rajulapati, Axis AMC)
- Answer: Capex ~₹252 crores including operations, currently under finalization. No call options exist on current O&M contracts; Gleneagles discussions with IHH are ongoing separately. (Vivek Goyal, Ashutosh Raghuvanshi)
M&A & Capital Allocation
- Question: What's capex guidance and M&A outlook? (Saion Mukherjee, Nomura)
- Answer: ~50% of EBITDA consumed for growth (brownfield + technology). M&A deals being pursued in focused clusters—unable to share details until concluded. (Vivek Goyal)
Attrition Trends
- Question: Is attrition rising in the hospital sector given industry expansion? (Saion Mukherjee, Nomura)
- Answer: Attrition spikes are micro-market specific (e.g., Noida with new hospital openings), not a broader trend. Supply of clinical talent is improving as doctors trained under expanded medical seats (15 years ago) complete their education—expect easing over next few years. (Ashutosh Raghuvanshi)
Key Takeaway
Fortis Healthcare delivered a steady Q1 FY27 with consolidated revenue of ₹2,545 crores (+17.5% YoY) and EBITDA of ₹568 crores (+15.8%), though margins compressed 30 bps YoY to 22.3% due to acquisition drag and one-off costs (legal, provisions). Hospital revenue grew 19% with 3,418 occupied beds (+17%) and stable 69% occupancy; Agilus grew 10.2% with EBITDA margin improvement to 23.9%. Management reaffirmed the 25% consolidated EBITDA margin target for FY28—now inclusive of the ₹160 crores annual ESOP charge—citing levers from new unit ramp-up (Manesar, Noida, FMRI), doctor productivity, cost normalization and provision recoveries. Strategic investments continue: 500 beds to be added in FY27, proton therapy (₹252 crores) at Gurugram, robotics across network, and a capital-light Qatar O&M entry in Odisha. Key watch points: oncology growth deceleration (5% vs 24% earlier) from chemo pricing reforms, ESOP execution risk, and diagnostics growth lag versus industry—all acknowledged by management with specific mitigation plans. With net debt-to-EBITDA at 1.01x and ~50% of EBITDA earmarked for growth, Fortis enters FY27 well-positioned to compound, contingent on successful execution of its brownfield ramp-up and new leadership at Agilus delivering the targeted 12-13% revenue growth and 24-25% EBITDA margin in the coming quarters.